Home> Products> peripheral insulin sensitivity

{ "products": [ { "_id": "67a35ad2c50c07ee3dcaceda", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Empagliflozin 12.5mg, Metformin Hydrochloride 1000mg", "description": "GLIEMPAFLOZIN MET 12.5mg/1000mg is an advanced combination medication formulated for the management of Type 2 Diabetes Mellitus. This dual-action therapy helps improve glycemic control by reducing blood sugar levels through two complementary mechanisms. It is ideal for individuals who require a combination of SGLT2 inhibition and biguanide therapy for effective blood sugar regulation. Along with a proper diet and regular exercise, this medication aids in better diabetes management and reduces the risk of diabetes-related complications.\n\n \nKey Benefits:\n \n\n Effective Blood Sugar Control – Helps lower HbA1c levels.\nWeight Management – Empagliflozin aids in weight loss by eliminating excess glucose through urine.\nCardiovascular Benefits – Reduces the risk of heart disease in diabetic patients.\nImproves Insulin Sensitivity – Enhances the body's response to insulin.\nSupports Kidney Function – Empagliflozin helps protect kidney function by reducing strain on the nephrons.\nReduces the Risk of Hypoglycemia – Unlike some other diabetes treatments, this combination has a lower risk of causing low blood sugar episodes.\n \nHow Does It Work?\n \n\nEmpagliflozin works by blocking SGLT2 (Sodium-Glucose Co-Transporter-2) in the kidneys, leading to the excretion of excess glucose through urine.\nMetformin decreases hepatic glucose production, slows glucose absorption from the intestines, and enhances insulin sensitivity in peripheral tissues.\nTogether, these mechanisms ensure better glycemic control while reducing the burden on the pancreas and insulin production.\n \nDirections for Use:\n \n\n Dosage: Take as prescribed by your healthcare provider.\nTiming: Usually taken once or twice daily with meals to reduce gastrointestinal side effects.\nSwallow Whole: Do not crush, chew, or break the tablet.\nLifestyle Recommendations: Maintain a healthy diet, regular physical activity, and weight management for best results.\n \nSide Effects:\n \n\nWhile GLIEMPAFLOZIN MET 12.5mg/1000mg is well-tolerated, some individuals may experience mild to moderate side effects, such as:\n\nFrequent urination (due to Empagliflozin)\nDehydration and low blood pressure\nGastrointestinal issues like nausea, diarrhea, or stomach upset\nYeast infections (especially in women)\nVitamin B12 deficiency (due to prolonged Metformin use)\nWarning: In rare cases, it may cause lactic acidosis or diabetic ketoacidosis. Consult your doctor immediately if you experience severe weakness, dizziness, difficulty breathing, or chest pain.", "price": 185.0, "discountamount": 56.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "lower risk", "nephrons reduces", "reducing strain", "weight management", "diabetes management", "chest pain", "doctor immediately", "lactic acidosis", "rare cases", "prolonged metformin", "nausea diarrhea", "experience mild", "crush chew", "glycemic control", "mechanisms ensure", "peripheral tissues", "kidneys leading", "diabetes treatments", "hypoglycemia unlike", "bodys response", "heart disease", "weight loss", "medication aids", "regular exercise", "proper diet", "biguanide therapy", "sglt2 inhibition", "complementary mechanisms", "empagliflozin dehydration", "excess glucose", "eliminating excess glucose", "work empagliflozin works", "diabetic ketoacidosis consult", "frequent urination due", "moderate side effects", "gliempaflozin met 125mg1000mg", "results side effects", "healthcare provider timing", "insulin production directions", "enhances insulin sensitivity" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2047, "imageuri": "https://productimages.withfloats.com/actual/67a35b5ff147b76947dad0ce.png", "tileimageuri": "https://productimages.withfloats.com/tile/67a35b5ff147b76947dad0ce.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-02-05T12:34:26.615Z", "updatedon": "2025-03-22T10:19:44.132Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/empagliflozin-12-5mg-metformin-hydrochloride-1000mg/2047", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIEMPAFLOZIN MET 12.5mg/ 1000mg ", "category": "", "tags": [ "empagliflozin 12.5 mg+metformin 500 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "674b0a7ee34075b8291b14f1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Glimepiride 0.5 mg, Voglibose 0.2 mg & Metformin Hydrochloride (SR) 500 mg Tablets", "description": "Diabetes management often requires a multifaceted approach to address the complexities of glucose regulation. Glimiteris Trio 0.5/0.2/500 offers a synergistic combination of three proven antidiabetic agents. This tablet not only targets fasting and postprandial blood glucose but also improves the body’s insulin utilization, ensuring better glycemic control and reducing the risk of complications associated with diabetes.\n\n \nKey Benefits:\nEffective Blood Sugar Management: Works on multiple pathways to control both fasting and postprandial blood glucose levels.\nReduces Insulin Resistance: Enhances the body's response to insulin, improving its efficacy.\nMinimizes Post-Meal Glucose Spikes: Voglibose slows carbohydrate digestion and absorption, keeping postprandial glucose in check.\nImproves Long-Term Glycemic Control: Helps in achieving and maintaining stable HbA1c levels.\nSustained Release Formula: Metformin’s SR formulation ensures prolonged action, reducing the need for frequent dosing.\nComprehensive Diabetes Management: Prevents complications like neuropathy, retinopathy, and cardiovascular issues associated with diabetes.\nHow Does It Work?\nGlimepiride: Stimulates the pancreas to release insulin, directly lowering blood glucose levels.\nVoglibose: Inhibits enzymes that break down carbohydrates into glucose, thereby delaying glucose absorption and controlling post-meal spikes.\nMetformin Hydrochloride SR: Decreases hepatic glucose production, enhances peripheral glucose uptake, and improves insulin sensitivity, ensuring balanced glucose levels throughout the day.\nTogether, these three ingredients address the multifaceted nature of type 2 diabetes, providing a holistic solution for effective blood sugar control.\n\nDirections for Use:\nDosage: Take one tablet as prescribed by your healthcare professional, usually once or twice daily with meals.\nSwallow Whole: Do not crush or chew the tablet; it is designed for sustained release.\nTiming: Preferably consume with a meal to reduce gastrointestinal discomfort and optimize efficacy.\nFollow Medical Advice: Stick to the prescribed dosage and schedule for optimal results.\nAlways consult your doctor before starting or adjusting your dosage.\n\nSide Effects:\nWhile Glimiteris Trio 0.5/0.2/500 is generally well-tolerated, some individuals may experience side effects, including:\n\nCommon Side Effects:\n\nNausea, vomiting, or diarrhea\nStomach discomfort or flatulence\nMild hypoglycemia (low blood sugar levels)\nRare but Serious Side Effects:\n\nSevere hypoglycemia\nLactic acidosis (from Metformin)\nAllergic reactions such as rash or itching\n\n", "price": 153.0, "discountamount": 46.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "prescribed dosage", "ingredients address", "glycemic control", "targets fasting", "generally welltolerated", "glimiteris trio 0502500", "optimal results", "meals swallow", "healthcare professional", "holistic solution", "multifaceted nature", "cardiovascular issues", "neuropathy retinopathy", "insulin improving", "bodys response", "multiple pathways", "synergistic combination", "multifaceted approach", "dosage side effects", "delaying glucose absorption", "postprandial blood glucose", "metformin allergic reactions", "diarrhea stomach discomfort", "experience side effects", "reduce gastrointestinal discomfort", "work glimepiride stimulates", "proven antidiabetic agents" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2016, "imageuri": "https://productimages.withfloats.com/actual/674b0a80ec7bb8b7dcae8a8a.png", "tileimageuri": "https://productimages.withfloats.com/tile/674b0a80ec7bb8b7dcae8a8a.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-11-30T12:52:14.799Z", "updatedon": "2024-11-30T12:52:14.799Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glimepiride-0-5-mg-voglibose-0-2-mg-metformin-hydrochloride-sr-500-mg-tablets/2016", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "GLIMITERIS TRIO 0.5/0.2/500 ", "category": "DIABETIC RANGE", "tags": [], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e8611b9f7300708fe1240", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIOGLIMITERIS 1/0.2 ", "description": "TRIOGLIMITERIS 1/0.2 \nVoglibose 0.2 mg, Glimepiride 1 mg & Metformin Hydrochloride 500 mg\nIntroduction\n\nTRIOGLIMITERIS 1/0.2 is a combination medication containing Voglibose, Glimepiride, and Metformin Hydrochloride. It is primarily used in the management of type 2 diabetes mellitus to improve glycemic control through different mechanisms of action targeting glucose metabolism.\n\nComposition\n\nVoglibose (0.2 mg): An alpha-glucosidase inhibitor that delays the digestion of carbohydrates in the intestine, thereby reducing postprandial blood glucose levels.\nGlimepiride (1 mg): A sulfonylurea derivative that stimulates insulin release from pancreatic beta cells, enhancing glucose uptake in peripheral tissues.\nMetformin Hydrochloride (500 mg): A biguanide that decreases hepatic glucose production, improves insulin sensitivity in peripheral tissues, and reduces intestinal glucose absorption.\nMechanism of Action\n\nTRIOGLIMITERIS 1/0.2 combines the actions of its components to achieve optimal glycemic control:\n\nVoglibose: Inhibits alpha-glucosidase enzymes in the intestine, delaying carbohydrate digestion and reducing the absorption of glucose after meals.\nGlimepiride: Stimulates insulin secretion from pancreatic beta cells in a glucose-dependent manner, thereby lowering blood glucose levels.\nMetformin Hydrochloride: Decreases hepatic glucose production through suppression of gluconeogenesis and enhances peripheral glucose uptake and utilization by improving insulin sensitivity.\nIndications\n\nTRIOGLIMITERIS 1/0.2 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults when diet, exercise, and monotherapy with metformin or sulfonylureas alone are not sufficient.\nDosage and Administration\n\nThe typical dosage of TRIOGLIMITERIS 1/0.2 is one tablet taken orally with meals, usually once or twice daily.\nDosage adjustments may be required based on individual patient response, blood glucose levels, and renal function.\nIt is essential to adhere to the prescribed dosage regimen to achieve optimal therapeutic outcomes.\nSide Effects\n\nCommon side effects of TRIOGLIMITERIS 1/0.2 may include:\n\nHypoglycemia (especially when used in combination with insulin or other antidiabetic medications)\nGastrointestinal disturbances (such as nausea, vomiting, diarrhea, or abdominal discomfort)\nWeight gain (mainly associated with sulfonylureas)\nMore severe side effects can include:\n\nAllergic reactions (rash, itching, swelling)\nLactic acidosis (rare but serious adverse effect associated with metformin use)\nHepatic dysfunction (monitor liver function tests periodically)\nPrecautions\n\nUse with caution in patients with renal impairment, hepatic dysfunction, or other significant medical conditions that may affect drug metabolism or excretion.\nRegular monitoring of blood glucose levels, renal function, and liver function is recommended during treatment with TRIOGLIMITERIS 1/0.2.\nAvoid use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.\nDrug Interactions\n\nTRIOGLIMITERIS 1/0.2 may interact with other medications affecting blood glucose levels, such as insulin, other oral antidiabetic agents, or drugs that affect renal function or hepatic metabolism. Close monitoring and dose adjustments may be necessary.\nConclusion\n\nTRIOGLIMITERIS 1/0.2 provides a comprehensive approach to managing type 2 diabetes mellitus by combining Voglibose, Glimepiride, and Metformin Hydrochloride. This combination targets different aspects of glucose metabolism, enhancing insulin secretion, reducing hepatic glucose production, and delaying carbohydrate absorption in the intestine. Proper dosage, administration, and monitoring for side effects are essential to achieve and maintain optimal glycemic control in diabetic patients using TRIOGLIMITERIS 1/0.2. Consultation with a healthcare provider is recommended for personalized treatment plans and management of diabetes with this medication.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n", "price": 195.0, "discountamount": 58.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "500 mg", "0.2 mg", "one tablet", "Weight gain", "Glimepiride 1", "metformin use", "Proper dosage", "Glimepiride (1", "dosage regimen", "typical dosage", "renal function", "insulin release", "drug metabolism", "Lactic acidosis", "Close monitoring", "dose adjustments", "renal impairment", "diabetic patients", "insulin secretion", "different aspects", "Drug Interactions", "other medications", "Regular monitoring", "Dosage adjustments", "Allergic reactions", "peripheral tissues", "hepatic metabolism", "glucose metabolism", "insulin sensitivity", "healthcare provider", "Hepatic dysfunction", "Common side effects", "abdominal discomfort", "different mechanisms", "liver function tests", "diabetic ketoacidosis", "pancreatic beta cells", "combination medication", "carbohydrate digestion", "comprehensive approach", "serious adverse effect", "Metformin Hydrochloride", "carbohydrate absorption", "sulfonylurea derivative", "glucose-dependent manner", "optimal glycemic control", "type 1 diabetes mellitus", "type 2 diabetes mellitus", "More severe side effects", "alpha-glucosidase enzymes", "peripheral glucose uptake", "hepatic glucose production", "alpha-glucosidase inhibitor", "individual patient response", "personalized treatment plans", "optimal therapeutic outcomes", "Gastrointestinal disturbances", "intestinal glucose absorption", "other antidiabetic medications", "other oral antidiabetic agents", "postprandial blood glucose levels", "other significant medical conditions" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1939, "imageuri": "https://productimages.withfloats.com/actual/668e86143a68154e11e7d822.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e86143a68154e11e7d822.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T13:01:05.875Z", "updatedon": "2024-07-10T13:01:05.875Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trioglimiteris-1-0-2-/1939", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIOGLIMITERIS 1/0.2 ", "category": "DIABETIC RANGE", "tags": [ "glimepiride 1mg+metformin 500mg+voglibose 0.2 mg", "Glimepiride 2mg Metformin 500mg Voglibose 0.2 mg b", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg", "voglibose glimepiride & metformin hydrochloride (s", "voglibose glimepiride + metformin hydrochloride us", "glimepiride 1mg+metformin 500mg+voglibose 0.3 mg", "glimepiride 2mg+metformin 500mg+voglibose 0.2 mg g", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "668e77e853fc1c2298508399", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PIO 20/15 ", "description": "TENELIGOLD PIO 20/15 \nTeneligliptin & Pioglitazone\nIntroduction\nTENELIGOLD PIO 20/15 combines two antidiabetic medications, Teneligliptin and Pioglitazone, in a single formulation. This combination is designed to manage type 2 diabetes mellitus by targeting different aspects of glucose metabolism, thereby improving glycemic control in patients who are inadequately controlled with monotherapy or require dual therapy.\n\nComposition\n\nTeneligliptin: A dipeptidyl peptidase-4 (DPP-4) inhibitor that enhances insulin secretion and reduces glucagon release, thereby lowering blood glucose levels.\nPioglitazone: A thiazolidinedione (TZD) that improves insulin sensitivity in peripheral tissues (muscle and adipose tissue) and reduces hepatic glucose production.\nMechanism of Action\n\nTeneligliptin: Inhibits the degradation of incretin hormones (GLP-1 and GIP), which play a key role in glucose-dependent insulin secretion and suppression of glucagon secretion.\nPioglitazone: Activates peroxisome proliferator-activated receptor gamma (PPAR-γ), leading to improved insulin sensitivity, enhanced glucose uptake in peripheral tissues, and reduced hepatic glucose production.\nIndications\nTENELIGOLD PIO 20/15 is indicated for:\n\nType 2 Diabetes Mellitus: Used to improve glycemic control in adults who are inadequately controlled with diet and exercise alone or with other antidiabetic medications.\nDosage and Administration\n\nThe typical dosage is one tablet of TENELIGOLD PIO 20/15 taken orally once daily, preferably with meals.\nDosage adjustments may be necessary based on individual patient response and tolerability.\nIt is important to adhere to the prescribed dosage regimen to achieve optimal glycemic control.\nSide Effects\nCommon side effects may include:\n\nHypoglycemia (especially when used in combination with insulin or sulfonylureas)\nEdema (fluid retention)\nWeight gain\nHeadache\nNasopharyngitis (common cold)\nMore severe side effects can include:\n\nHeart failure (especially in patients with pre-existing cardiovascular disease)\nHepatic dysfunction (monitor liver function tests periodically)\nBone fractures (especially in women)\nPrecautions\n\nHeart Failure: Use with caution in patients with a history of heart failure or other cardiovascular diseases.\nBladder Cancer: Pioglitazone has been associated with an increased risk of bladder cancer; therefore, it should be used cautiously in patients with a history of bladder cancer or with risk factors.\nLiver Function: Monitor liver function tests before starting treatment and periodically thereafter, as Pioglitazone may cause hepatic dysfunction.\nPregnancy and Lactation: Use during pregnancy and lactation should be avoided unless the potential benefits outweigh the risks.\nDrug Interactions\n\nInsulin/Sulfonylureas: Increased risk of hypoglycemia when used concomitantly with insulin or sulfonylureas.\nGemfibrozil: May increase Pioglitazone levels, requiring dose adjustment.\nCYP2C8 Inhibitors (e.g., Gemfibrozil): May increase Pioglitazone concentrations, necessitating monitoring for adverse effects.\nConclusion\nTENELIGOLD PIO 20/15 offers a dual-action approach to managing type 2 diabetes mellitus by combining Teneligliptin and Pioglitazone. This combination helps improve glycemic control through different mechanisms: enhancing insulin secretion and sensitivity. It is crucial to use this medication under the guidance of a healthcare professional to optimize treatment outcomes while minimizing the risk of side effects. Regular monitoring for efficacy and safety parameters, including blood glucose levels and potential adverse effects, is essential for managing diabetes effectively with TENELIGOLD PIO 20/15.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order NOW\n\n", "price": 149.0, "discountamount": 44.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "key role", "one tablet", "Weight gain", "common cold", "risk factors", "dual therapy", "Heart failure", "increased risk", "dosage regimen", "typical dosage", "Bladder Cancer", "Bone fractures", "adipose tissue", "TENELIGOLD PIO", "glucose uptake", "dose adjustment", "fluid retention", "glucagon release", "DPP-4) inhibitor", "safety parameters", "CYP2C8 Inhibitors", "Drug Interactions", "incretin hormones", "different aspects", "Regular monitoring", "treatment outcomes", "Dosage adjustments", "peripheral tissues", "single formulation", "glucagon secretion", "potential benefits", "glucose metabolism", "insulin sensitivity", "Pioglitazone levels", "Hepatic dysfunction", "Common side effects", "different mechanisms", "dual-action approach", "liver function tests", "blood glucose levels", "dipeptidyl peptidase-4", "healthcare professional", "optimal glycemic control", "type 2 diabetes mellitus", "More severe side effects", "potential adverse effects", "hepatic glucose production", "Pioglitazone concentrations", "individual patient response", "two antidiabetic medications", "other cardiovascular diseases", "other antidiabetic medications", "existing cardiovascular disease", "glucose-dependent insulin secretion", "peroxisome proliferator-activated receptor gamma" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1935, "imageuri": "https://productimages.withfloats.com/actual/668e77ebf07c99c3af8e6d67.jpeg", "tileimageuri": "https://productimages.withfloats.com/tile/668e77ebf07c99c3af8e6d67.jpeg", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-07-10T12:00:40.528Z", "updatedon": "2024-07-10T12:00:40.528Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//teneligold-pio-20-15-/1935", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PIO 20/15 ", "category": "DIABETIC RANGE", "tags": [ "teneligliptin + pioglitazone brand name", "Zita Plus Pio", "Teneligliptin + Pioglitazone Metformin", "Zita Piomet 1000", "Teneligliptin 20 MG and Pioglitazone 15 MG tablets", "Dapagliflozin", "Zita Piomet 500" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6662c4c88ecffe165c354dc1", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "VILDIABATE PIO ", "description": "VILDIABATE PIO \nVildagliptin 50 mg & Pioglitazone Hydrochloride 15 mg\nIntroduction to VILDIABATE PIO\nVILDIABATE PIO is a combination medication designed for the effective management of type 2 diabetes mellitus. It contains two active ingredients: Vildagliptin 50mg and Pioglitazone Hydrochloride 15mg. This dual-action formula targets different aspects of glucose regulation, providing comprehensive blood sugar control. It is used alongside diet and exercise to improve glycemic control in adults with type 2 diabetes.\n\nKey Components and Their Mechanisms\nVildagliptin 50mg\nVildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by:\n\nEnhancing Incretin Levels: Vildagliptin inhibits the DPP-4 enzyme, which degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones increase insulin secretion and decrease glucagon release in a glucose-dependent manner.\nImproving Postprandial Glucose Control: By enhancing the action of incretin hormones, Vildagliptin helps regulate blood sugar levels after meals.\nPioglitazone Hydrochloride 15mg\nPioglitazone is a thiazolidinedione that improves insulin sensitivity in muscle and adipose (fat) tissues. It works by:\n\nIncreasing Insulin Sensitivity: Pioglitazone enhances the body's response to insulin, allowing for better glucose uptake and utilization by cells.\nReducing Hepatic Glucose Production: Pioglitazone decreases the amount of glucose produced by the liver, helping to lower fasting blood sugar levels.\nBenefits of VILDIABATE PIO\nComprehensive Blood Sugar Control\nFasting and Postprandial Glucose Management: The combination of Vildagliptin and Pioglitazone effectively manages both fasting and postprandial (after-meal) blood sugar levels.\nImproved Insulin Sensitivity and Secretion: Vildagliptin enhances insulin secretion in response to meals, while Pioglitazone improves insulin sensitivity in peripheral tissues.\nAdditional Health Benefits\nLow Risk of Hypoglycemia: Vildagliptin has a low risk of causing hypoglycemia (low blood sugar) because it enhances insulin secretion only when blood glucose levels are elevated.\nCardioprotective Effects: Pioglitazone may provide additional cardiovascular benefits, such as improving lipid profiles and reducing inflammation, which can be beneficial for patients with diabetes who are at risk of cardiovascular diseases.\nWeight Management: While Pioglitazone may cause some weight gain due to fluid retention, Vildagliptin is generally weight neutral, balancing the overall effect on body weight.\nDosage and Administration\nRecommended Dosage\nDosage: The typical dosage of VILDIABATE PIO is one tablet taken once daily, preferably with a meal to enhance absorption and reduce gastrointestinal side effects.\nAdministration: Swallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nGuidelines for Optimal Use\nConsistent Use: For best results, take VILDIABATE PIO regularly at the same time each day as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regular monitoring of blood sugar levels is essential to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/vildiabate-pio-134257\n", "price": 295.0, "discountamount": 88.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "diet", "Order", "meals", "EMAIL", "cells", "liver", "water", "glass", "GLP-1", "amount", "muscle", "adults", "Fasting", "adipose", "patients", "Low Risk", "exercise", "readings", "response", "Enhancing", "same time", "one tablet", "Mechanisms", "Increasing", "Guidelines", "absorption", "utilization", "Optimal Use", "information", "body weight", "Adjustments", "weight gain", "DPP-4 enzyme", "inflammation", "Introduction", "Vildagliptin", "Hypoglycemia", "sterispharma", "best results", "fat) tissues", "sterisonline", "CALL/WHATSAPP", "Administration", "VILDIABATE PIO", "glucose uptake", "Key Components", "Consistent Use", "treatment plan", "overall effect", "lipid profiles", "typical dosage", "Incretin Levels", "low blood sugar", "fluid retention", "glycemic control", "glucagon release", "DPP-4) inhibitor", "Weight Management", "insulin secretion", "incretin hormones", "different aspects", "thiazolidinedione", "peripheral tissues", "glucose regulation", "Regular monitoring", "healthcare provider", "dual-action formula", "insulin sensitivity", "blood glucose levels", "effective management", "dipeptidyl peptidase-4", "two active ingredients", "combination medication", "cardiovascular diseases", "Cardioprotective Effects", "type 2 diabetes mellitus", "meal) blood sugar levels", "glucose-dependent manner", "Recommended Dosage Dosage", "Pioglitazone Hydrochloride", "Additional Health Benefits", "Hepatic Glucose Production", "gastrointestinal side effects", "Postprandial Glucose Management", "comprehensive blood sugar control", "additional cardiovascular benefits", "Improving Postprandial Glucose Control", "glucose-dependent insulinotropic peptide" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1512, "imageuri": "https://productimages.withfloats.com/actual/667d3d8c5443982e2f655655.png", "tileimageuri": "https://productimages.withfloats.com/tile/667d3d8c5443982e2f655655.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-07T08:28:56.298Z", "updatedon": "2024-06-27T10:23:02.274Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//vildiabate-pio-/1512", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "VILDIABATE PIO ", "category": "DIABETIC RANGE", "tags": [ "vildagliptin metformin hydrochloride tablets uses", "vildagliptin + metformin + glimepiride combination", "vildagliptin 50 mg side effects", "vildagliptin and pioglitazone hydrochloride" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661afd366170d1ff8cb4626", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 60 ", "description": "TRIGLICLAGLAZE 60 \nGliclazide 60mg (SR) Pioglitazone 15mg and Metformin HCL 500mg(SR)\nTRIGLICLAGLAZE 60 is a combination medication designed to effectively manage type 2 diabetes mellitus by addressing multiple aspects of glucose regulation. It combines three key components: Gliclazide 60mg (SR), Pioglitazone 15mg, and Metformin HCI 500mg (SR), each contributing to improved blood sugar control through distinct mechanisms of action.\n\nGliclazide 60mg (SR): Gliclazide is a sulfonylurea medication that stimulates the pancreas to release insulin. This insulin release helps lower blood sugar levels, especially after meals, by facilitating glucose uptake into cells.\n\nPioglitazone 15mg: Pioglitazone belongs to the thiazolidinedione class and works by improving insulin sensitivity in peripheral tissues such as muscle and fat cells. Enhanced insulin sensitivity allows for better utilization of glucose, reducing insulin resistance and promoting more efficient blood sugar management.\n\nMetformin HCI 500mg (SR): Metformin is a biguanide medication that primarily works by reducing glucose production in the liver and increasing insulin sensitivity in muscle cells. It also improves glucose uptake by cells and reduces the absorption of glucose from the digestive tract.\n\nKey Benefits of TRIGLICLAGLAZE 60:\nComprehensive Glucose Control: By combining Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), TRIGLICLAGLAZE 60 offers comprehensive control over blood sugar levels throughout the day.\n\nStimulates Insulin Release: Gliclazide's action in stimulating insulin release from the pancreas helps manage postprandial (after-meal) glucose spikes, contributing to overall glucose control.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in tissues, leading to better glucose uptake and utilization by cells. This helps reduce insulin resistance, a common feature of type 2 diabetes.\n\nReduces Glucose Production: Metformin HCI lowers glucose production in the liver and improves insulin action in muscle cells, leading to lower fasting blood sugar levels and enhanced glucose utilization.\n\nExtended Release Formulation: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, providing consistent blood sugar control and minimizing the risk of hypoglycemia or hyperglycemia.\n\nDosage and Administration:\nTRIGLICLAGLAZE 60 is typically taken orally once or twice daily, with meals to reduce gastrointestinal side effects.\nDosage adjustments may be required based on blood sugar levels and individual response to treatment. Follow your healthcare provider's instructions.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-60-134279", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "SR", "day", "risk", "meals", "Order", "liver", "EMAIL", "gradual", "fasting", "pancreas", "Enhanced", "treatment", "fat cells", "absorption", "information", "medications", "muscle cells", "Pioglitazone", "sterisonline", "Key Benefits", "hypoglycemia", "instructions", "sterispharma", "postprandial", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "Administration", "glucose uptake", "TRIGLICLAGLAZE", "common feature", "glucose spikes", "insulin action", "insulin release", "Gliclazide 60mg", "digestive tract", "multiple aspects", "prolonged release", "Dosage adjustments", "peripheral tissues", "blood sugar levels", "glucose production", "insulin resistance", "glucose regulation", "distinct mechanisms", "healthcare provider", "individual response", "glucose utilization", "insulin sensitivity", "three key components", "biguanide medication", "comprehensive control", "combination medication", "sulfonylurea medication", "thiazolidinedione class", "overall glucose control", "type 2 diabetes mellitus", "Extended Release Formulation", "Comprehensive Glucose Control", "gastrointestinal side effects", "sustained-release formulations", "consistent blood sugar control", "efficient blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1485, "imageuri": "https://productimages.withfloats.com/actual/6661afd7f21358d53af3cd71.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661afd7f21358d53af3cd71.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:47:15.16Z", "updatedon": "2024-06-28T12:12:27Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM//trigliclaglaze-60-/1485", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 60 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 60", "Gliclazide 60mg (SR)", "Pioglitazone 15mg", "Metformin HCL 500mg(SR)", "Metformin SR 500mg uses", "Metformin SR 500 price", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661af452bed1f08484d625b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRIGLICLAGLAZE 30 ", "description": "TRIGLICLAGLAZE 30 \nGliclazide (SR) Pioglitazone and Metformin HCL (SR)\nTRIGLICLAGLAZE 30 is a combination medication formulated to manage type 2 diabetes mellitus effectively. It combines three key components: Gliclazide (SR), Pioglitazone, and Metformin HCI (SR), each targeting different aspects of glucose regulation to achieve optimal blood sugar control.\n\nGliclazide (SR): Gliclazide is a sulfonylurea medication that works by stimulating the pancreas to release insulin, which helps lower blood sugar levels. The sustained-release (SR) formulation ensures a gradual and prolonged release of the medication, providing consistent glucose-lowering effects throughout the day.\n\nPioglitazone: Pioglitazone belongs to the thiazolidinedione class of drugs and enhances insulin sensitivity in muscle and fat tissues. By improving the body's response to insulin, Pioglitazone helps reduce insulin resistance and promotes better glucose utilization by cells.\n\nMetformin HCI (SR): Metformin is a biguanide medication that works primarily by reducing glucose production in the liver and increasing insulin sensitivity in peripheral tissues. The sustained-release formulation ensures a gradual release of Metformin, minimizing gastrointestinal side effects and providing extended blood sugar control.\n\nKey Benefits of TRIGLICLAGLAZE 30:\nComprehensive Glucose Control: The combination of Gliclazide (SR), Pioglitazone, and Metformin HCI (SR) targets multiple pathways involved in glucose metabolism. This comprehensive approach helps achieve better overall blood sugar control throughout the day.\n\nStimulates Insulin Release: Gliclazide stimulates insulin secretion from the pancreas, especially after meals, which is crucial for managing postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Pioglitazone enhances insulin sensitivity in muscle and fat tissues, allowing for better glucose uptake and utilization by cells. This action helps reduce insulin resistance, a hallmark of type 2 diabetes.\n\nReduces Hepatic Glucose Production: Metformin HCI (SR) reduces the production of glucose in the liver, helping to lower fasting blood sugar levels and prevent excessive glucose release into the bloodstream.\n\nExtended Blood Sugar Control: The sustained-release formulations of Gliclazide and Metformin ensure a gradual and prolonged release of the medications, leading to consistent blood sugar control and minimizing the risk of hypoglycemia (low blood sugar) or hyperglycemia (high blood sugar) fluctuations.\n\nDosage and Administration:\nTRIGLICLAGLAZE 30 is typically taken orally once or twice daily, as prescribed by a healthcare provider.\nThe medication is often taken with meals to reduce the risk of gastrointestinal side effects.\nDosage adjustments may be necessary based on blood sugar levels and individual response to treatment. Follow your doctor's instructions carefully.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/trigliclaglaze-30-134278", "price": 125.0, "discountamount": 37.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "day", "body", "risk", "drugs", "meals", "Order", "liver", "cells", "EMAIL", "doctor", "muscle", "action", "pancreas", "hallmark", "treatment", "Gliclazide", "fat tissues", "information", "medications", "bloodstream", "Pioglitazone", "sterisonline", "postprandial", "hypoglycemia", "fluctuations", "instructions", "sterispharma", "Key Benefits", "hyperglycemia", "CALL/WHATSAPP", "Metformin HCL", "Metformin HCI", "glucose uptake", "Administration", "TRIGLICLAGLAZE", "low blood sugar", "gradual release", "Insulin Release", "high blood sugar", "prolonged release", "insulin secretion", "different aspects", "multiple pathways", "peripheral tissues", "insulin resistance", "Dosage adjustments", "blood sugar levels", "glucose metabolism", "glucose regulation", "glucose utilization", "individual response", "insulin sensitivity", "healthcare provider", "meal) glucose spikes", "three key components", "biguanide medication", "combination medication", "comprehensive approach", "thiazolidinedione class", "sulfonylurea medication", "type 2 diabetes mellitus", "excessive glucose release", "Hepatic Glucose Production", "overall blood sugar control", "optimal blood sugar control", "extended blood sugar control", "gastrointestinal side effects", "sustained-release formulation", "Comprehensive Glucose Control", "consistent blood sugar control", "sustained-release (SR) formulation", "consistent glucose-lowering effects" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1484, "imageuri": "https://productimages.withfloats.com/actual/6661af49f21358d53af3ccec.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661af49f21358d53af3ccec.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:44:53.071Z", "updatedon": "2024-06-28T12:15:14.626Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trigliclaglaze-30-/1484", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRIGLICLAGLAZE 30 ", "category": "DIABETIC RANGE", "tags": [ "TRIGLICLAGLAZE 30", "Gliclazide (SR)", "Pioglitazone", "Metformin HCL (SR)", "Metformin SR 500mg uses", "Metformin hydrochloride 500 mg", "Metformin SR 500 side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661aea4d91d281c30c76019", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRI GLIBEN FORTE ", "description": "TRI GLIBEN FORTE \nGlibenclamide (5mg), Metformin HCI (500mg), Pioglitazone (15mg)\nTRI GLIBEN FORTE is a combination medication containing Glibenclamide, Metformin HCI, and Pioglitazone. This combination is commonly prescribed for the management of type 2 diabetes mellitus, a condition characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nGlibenclamide (5mg): Glibenclamide belongs to the sulfonylurea class of medications. It works by stimulating the pancreas to release insulin, thereby lowering blood sugar levels. Glibenclamide also helps the body use insulin more effectively.\n\nMetformin HCI (500mg): Metformin is a biguanide medication that reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. It is a first-line treatment for type 2 diabetes and helps improve overall glycemic control.\n\nPioglitazone (15mg): Pioglitazone is a thiazolidinedione medication that improves insulin sensitivity in muscle and adipose (fat) tissues. It reduces glucose production in the liver and enhances glucose uptake in peripheral tissues, leading to better blood sugar control.\n\nKey Benefits of TRI GLIBEN FORTE:\nComprehensive Glucose Control: The combination of Glibenclamide, Metformin HCI, and Pioglitazone targets multiple pathways involved in glucose metabolism, providing comprehensive control over blood sugar levels.\n\nStimulates Insulin Release: Glibenclamide stimulates insulin secretion from the pancreas, especially after meals, helping to regulate postprandial (after-meal) glucose spikes.\n\nImproves Insulin Sensitivity: Metformin and Pioglitazone improve insulin sensitivity in cells, allowing for better utilization of glucose and reducing insulin resistance.\n\nReduces Hepatic Glucose Production: Metformin and Pioglitazone both reduce the production of glucose in the liver, helping to lower fasting blood sugar levels.\n\nCardiometabolic Benefits: Pioglitazone may have additional benefits for cardiovascular health, such as reducing inflammation and improving lipid profiles.\n\nDosage and Administration:\nThe typical dosage of TRI GLIBEN FORTE is one tablet taken orally once or twice daily, as prescribed by your healthcare provider.\nIt is usually taken with meals to reduce the risk of gastrointestinal side effects.\nFollow your doctor's instructions regarding dosage adjustments based on your blood sugar levels and response to treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/tri-gliben-forte-133450", "price": 74.0, "discountamount": 22.2, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "body", "risk", "Order", "500mg", "EMAIL", "liver", "meals", "cells", "muscle", "doctor", "adipose", "response", "pancreas", "condition", "management", "one tablet", "utilization", "information", "medications", "Pioglitazone", "sterispharma", "Key Benefits", "fat) tissues", "instructions", "postprandial", "inflammation", "sterisonline", "CALL/WHATSAPP", "Metformin HCI", "Glibenclamide", "Administration", "typical dosage", "glucose uptake", "lipid profiles", "Insulin Release", "TRI GLIBEN FORTE", "insulin secretion", "multiple pathways", "dosage adjustments", "glucose metabolism", "peripheral tissues", "sulfonylurea class", "insulin resistance", "blood sugar control", "healthcare provider", "insulin sensitivity", "additional benefits", "biguanide medication", "first-line treatment", "meal) glucose spikes", "cardiovascular health", "comprehensive control", "combination medication", "high blood sugar levels", "overall glycemic control", "Cardiometabolic Benefits", "type 2 diabetes mellitus", "Hepatic Glucose Production", "thiazolidinedione medication", "intestinal glucose absorption", "Comprehensive Glucose Control", "gastrointestinal side effects", "inadequate insulin production" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1483, "imageuri": "https://productimages.withfloats.com/actual/6661aea6dd39d2ccddbc8e54.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661aea6dd39d2ccddbc8e54.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:42:12.134Z", "updatedon": "2024-06-28T12:16:49.307Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/tri-gliben-forte-/1483", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRI GLIBEN FORTE ", "category": "DIABETIC RANGE", "tags": [ "TRI GLIBEN FORTE", "Glibenclamide (5mg)", "Metformin HCI (500mg)", "Pioglitazone (15mg)", "Pioglitazone 15 mg uses", "Pioglitazone side effects", "Pioglitazone uses" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6661adf866170d1ff8cb45d2", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TENELIGOLD PM 500 ", "description": "TENELIGOLD PM 500 \nTeneligliptin 20mg, Pioglitazone 15mg & Extended Release Metformin Hydrochloride 500mg\nTENELIGOLD PM 500 is a combination medication containing Teneligliptin, Pioglitazone, and Extended-Release Metformin Hydrochloride. It is primarily prescribed for the management of type 2 diabetes mellitus, a metabolic disorder characterized by high blood sugar levels due to insulin resistance or inadequate insulin production.\n\nTeneligliptin (20mg): Teneligliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. It works by inhibiting the DPP-4 enzyme, which enhances the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These hormones stimulate insulin secretion and inhibit glucagon release, leading to improved glucose control after meals.\n\nPioglitazone (15mg): Pioglitazone is a thiazolidinedione medication that improves insulin sensitivity in muscle and adipose (fat) tissues. It reduces glucose production in the liver and enhances glucose uptake in peripheral tissues. This action helps lower blood sugar levels and improves overall glycemic control.\n\nExtended-Release Metformin Hydrochloride (500mg): Metformin is a biguanide medication that reduces glucose production in the liver, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. Extended-release formulations provide a sustained release of the drug, allowing for once-daily dosing and potentially reducing gastrointestinal side effects.\n\nKey Benefits of TENELIGOLD PM 500:\nComprehensive Glycemic Control: The combination of Teneligliptin, Pioglitazone, and Extended-Release Metformin offers comprehensive control over fasting and postprandial (after-meal) blood sugar levels.\n\nImproved Insulin Sensitivity: Pioglitazone and Metformin work synergistically to improve insulin sensitivity in cells, leading to better utilization of glucose and reduced insulin resistance.\n\nIncretin Hormone Enhancement: Teneligliptin enhances the action of incretin hormones, which regulate insulin secretion and glucagon levels, resulting in improved glucose regulation after meals.\n\nReduced Side Effects: Extended-release formulations of Metformin may reduce gastrointestinal side effects compared to immediate-release formulations.\n\nDosage and Administration:\nThe typical dosage of TENELIGOLD PM 500 is one tablet taken orally once daily, preferably with meals.\nSwallow the tablet whole with a glass of water. Do not crush, chew, or split the tablet unless advised by your healthcare provider.\nFollow your doctor's instructions regarding dosage adjustments based on your medical condition and response to treatment.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/teneligold-pm-500-134300", "price": 180.0, "discountamount": 54.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "GIP", "meals", "500mg", "EMAIL", "cells", "drugs", "GLP-1", "liver", "glass", "water", "dosing", "muscle", "action", "doctor", "fasting", "response", "treatment", "management", "one tablet", "utilization", "information", "postprandial", "Pioglitazone", "Key Benefits", "fat) tissues", "sterisonline", "sterispharma", "instructions", "DPP-4 enzyme", "CALL/WHATSAPP", "TENELIGOLD PM", "Teneligliptin", "glucose uptake", "Administration", "typical dosage", "glucose control", "glucagon levels", "glucagon release", "incretin hormones", "insulin secretion", "sustained release", "medical condition", "dosage adjustments", "metabolic disorder", "glucose regulation", "peripheral tissues", "insulin resistance", "glucose production", "healthcare provider", "insulin sensitivity", "biguanide medication", "Reduced Side Effects", "comprehensive control", "combination medication", "DPP-4) inhibitor class", "dipeptidyl peptidase-4", "high blood sugar levels", "overall glycemic control", "type 2 diabetes mellitus", "meal) blood sugar levels", "Incretin Hormone Enhancement", "thiazolidinedione medication", "Extended-release formulations", "inadequate insulin production", "intestinal glucose absorption", "gastrointestinal side effects", "Comprehensive Glycemic Control", "immediate-release formulations", "Extended-Release Metformin Hydrochloride", "glucose-dependent insulinotropic peptide", "Extended Release Metformin Hydrochloride" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1481, "imageuri": "https://productimages.withfloats.com/actual/6661adfd637f8700d7ca4512.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661adfd637f8700d7ca4512.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T12:39:20.713Z", "updatedon": "2024-06-28T12:21:18.417Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/teneligold-pm-500-/1481", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TENELIGOLD PM 500 ", "category": "DIABETIC RANGE", "tags": [ "TENELIGOLD PM 500", "Teneligliptin 20mg", "Pioglitazone 15mg", "Metformin Hydrochloride 500mg", "Teneligliptin Tablets 20 mg uses", "Teneligliptin 20 mg + Metformin 500", "Teneligliptin 20 mg side effects" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }